Literature DB >> 3986790

Photosensitization and split-dose recovery in cultured human urinary bladder carcinoma cells containing nonexchangeable hematoporphyrin derivative.

D A Bellnier, C W Lin.   

Abstract

The photosensitization and survival recovery of cultured EJ human urinary bladder carcinoma cells containing nonexchangeable hematoporphyrin derivative (HPD) were studied. Cultures were incubated at 37 degrees C in growth medium supplemented with HPD (50 micrograms/ml) and 5% fetal bovine serum for 12 h followed by incubation in HPD-free medium containing 5% fetal bovine serum for 9 or 18 h. The levels of porphyrin remaining in the cells (termed the "nonexchangeable" intracellular porphyrin component) were not significantly different at these times, and as a result sensitivities to broad-band red light (greater than 580 nm) were also identical. Shouldered survival curves were obtained in each case, indicating the ability to accumulate sublethal photodamage. Recovery from photosensitized damage using a split-dose technique was examined. Single, attached, asynchronously growing cells containing nonexchangeable HPD (12 h HPD uptake plus 9 h in porphyrin-free medium) were exposed to red light (1.2 kJ/sq m) and, after various intervals at 37 degrees C in the dark, a second dose of 1.2 kJ/sq m. Survival rapidly increased and reached a maximum at about 9 h between light doses. Analysis of dose-response curves revealed a partial reappearance of the curve shoulder (Dq = 0.22 kJ/sq m) and a markedly reduced curve slope (D0 = 0.82 kJ/sq m) for fractionated irradiations with a 9-h interval in comparison with graded, single light exposures (Dq = 0.48 kJ/sq m; D0 = 0.41 kJ/sq m). These observations suggest that the cells developed an increased tolerance to photosensitized damage after prior HPD-light treatment. No significant change in intracellular HPD levels between irradiations was detected, indicating that the increased survival was not due to a loss of sensitizer from inside the cells. These results demonstrate that EJ cells accumulate and recover from HPD-sensitized photodamage; analogous to the accumulation and recovery from sublethal damage (Elkind recovery) in other mammalian cultures treated with ionizing radiation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986790

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Effect of photofrin II and light energy on retinoblastoma-like cells in vitro. Dose-response relationships, effect of light dose rate and recovery ratio.

Authors:  J Winther
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.

Authors:  Mukund Seshadri; David A Bellnier; Lurine A Vaughan; Joseph A Spernyak; Richard Mazurchuk; Thomas H Foster; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 3.  Photodynamic therapy in the treatment of cancer: current state of the art.

Authors:  R A Hsi; D I Rosenthal; E Glatstein
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

4.  The photodynamic effect of a pulsed dye laser on human bladder carcinoma cells in vitro.

Authors:  A J Pope; J R Masters; A J MacRobert
Journal:  Urol Res       Date:  1990

5.  The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids.

Authors:  Marlon S Mathews; Even Angell-Petersen; Rogelio Sanchez; Chung-Ho Sun; Van Vo; Henry Hirschberg; Steen J Madsen
Journal:  Lasers Surg Med       Date:  2009-10       Impact factor: 4.025

6.  Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma.

Authors:  L W Ma; J Moan; H B Steen; V Iani
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

7.  The effect of fractionation of light treatment on necrosis and vascular function of normal skin following photodynamic therapy.

Authors:  K Benstead; J V Moore
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.